- 全部删除
 
您的购物车当前为空
Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.

Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 25 mg | ¥ 22,100  | 6-8周 | |
| 50 mg | ¥ 29,100  | 6-8周 | |
| 100 mg | ¥ 36,800  | 6-8周 | 
Naveglitazar 相关产品
| 产品描述 | Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.  | 
| 别名 | LY-9818, LY9818, LY-519818, LY519818, LY 9818, LY 519818 | 
| 分子量 | 422.47 | 
| 分子式 | C25H26O6 | 
| CAS No. | 476436-68-7 | 
| 密度 | no data available | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
评论内容